EcoDrugPlus

Proteasome 20s Subunit Beta 10

Ensembl ID : ENSDARG00000043781
Gene Symbol: PSMB10
122 Enzyme and pathways 5 Cross references
172 Possible Orthologues:

Proteasome 20s Subunit Beta 11a

Ensembl ID : ENSDARG00000108530
Gene Symbol: PSMB11A
4 Cross references
170 Possible Orthologues:

Proteasome 20s Subunit Beta 11b

Ensembl ID : ENSDARG00000068086
Gene Symbol: PSMB11B
112 Enzyme and pathways 5 Cross references
161 Possible Orthologues:

Proteasome 20s Subunit Beta 2

Ensembl ID : ENSDARG00000031511
Gene Symbol: PSMB2
122 Enzyme and pathways 5 Cross references
222 Possible Orthologues:

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSDARG00000013938
Gene Symbol: PSMB3
122 Enzyme and pathways 5 Cross references
261 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSDARG00000054696
Gene Symbol: PSMB4
122 Enzyme and pathways 5 Cross references
215 Possible Orthologues:

Proteasome 20s Subunit Beta 5

Ensembl ID : ENSDARG00000075445
Gene Symbol: PSMB5
122 Enzyme and pathways 5 Cross references
223 Possible Orthologues:

Proteasome 20s Subunit Beta 6

Ensembl ID : ENSDARG00000002240
Gene Symbol: PSMB6
122 Enzyme and pathways 5 Cross references
228 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSDARG00000037962
Gene Symbol: PSMB7
123 Enzyme and pathways 5 Cross references
216 Possible Orthologues:

Proteasome 20s Subunit Beta 8a

Ensembl ID : ENSDARG00000001303
Gene Symbol: PSMB8A
122 Enzyme and pathways 5 Cross references
221 Possible Orthologues:

Proteasome 20s Subunit Beta 9a

Ensembl ID : ENSDARG00000000656
Gene Symbol: PSMB9A
122 Enzyme and pathways 5 Cross references
211 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSDARG00000099653
Gene Symbol: PSMD2
123 Enzyme and pathways 3 Cross references
215 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).